BioSpace News Archive

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules.

Invacare Corporation, a leading manufacturer and distributor of medical equipment used in non-acute care settings, announced actions to strengthen the company and position it for long-term success.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Breast Cancer were updated to include an addition involving neratinib (NERLYNX ® ).

Neovasc, Inc. announced the German Institute for the Hospital Remuneration System has awarded the Neovasc Reducer™, a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.

Qualigen Therapeutics, Inc. today issued the following letter to its stockholders.

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) announced today the formation of its Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease and atrial fibrillation (ESRD + AFib).

PX Solutions, is launching to enable hospitals and long term care centres to improve patient and caregiver experiences and improve patient outcomes.

ROMEG Therapeutics, LLC (“Romeg”), an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,564,909 (the ‘909 patent) directed to the methods and composition of ROMEG’s proprietary formulation of pilocarpine.

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Eli Lilly to be a specialty pharmacy partner for JAYPIRCA™ (pirtobrutinib), which is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor (BTKi).

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed Chief Financial Officer, effective immediately.